Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANO-PSO
- Development stage
- Unknown
- Lead developer
- Granalix
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
**NANO-PSO** is a nano-formulation of pomegranate seed oil, designed to enhance delivery of its active component, punicic acid (omega-5), and its neuroprotective metabolite, conjugated linoleic acid, to the brain. By utilizing nanotechnology to create an oil-in-water nanoemulsion, the formulation increases brain bioavailability and has shown effects in animal models and early clinical development in mitigating cognitive decline and neuronal cell loss associated with traumatic brain injury (TBI), Alzheimer's disease models, genetic Creutzfeldt-Jakob disease, and perimenopausal vasomotor symptoms. Its purported mechanisms are primarily antioxidant, anti-inflammatory, and cytoprotective, reducing oxidative stress, neuronal death, reactive gliosis, and mitochondrial dysfunction. NANO-PSO increases levels of neuroprotective proteins (SIRT1, synaptophysin) and preserves mitochondrial cytochrome C oxidase (COX IV1) activity.
- Brand names
- Granagard
- Other names
- nanoemulsified pomegranate seed oilnano-pso
02
Targets
COX7C (Cytochrome c oxidase subunit 7C, mitochondrial)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on NANO-PSO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANO-PSO.